Chelsea Green Publishing

The Blogging Community at Chelsea Green

Scientific Review: “There Is Now Clear Evidence That Cannabinoids Are Useful For The Treatment Of Various Medical Conditions”

For the second time in recent months, a scientific paper published in a peer-reviewed journal has thoroughly rebutted the present Schedule I status of cannabis under US federal law, which states that the plant and its organic constituents possess a “high potential for abuse,” and that they lack “accepted medical use” and “accepted safety … under medical supervision.” According to a just published review in the German scientific journal Deutsches Ärzteblatt International, scientific findings from over 100 controlled clinical trials involving either cannabis or its constituents provide “clear evidence that cannabinoids are useful for the treatment of various medical conditions.” Investigators from the nova-Institute and the Hannover Medical School in Germany reviewed over 100 controlled trials assessing the safety and efficacy of cannabis and cannabinoids. Researchers reported: “Knowledge about the therapeutic potential of cannabis products has been greatly improved by a large number of clinical trials in recent years. … There is now clear evidence that cannabinoids are useful for the treatment of various medical conditions,” including chronic neuropathy (nerve pain), multiple sclerosis, HIV/AIDS, Gilles de la Tourette syndrome, and other indications. Regarding the safety profile of cannabis and cannabinoids, investigators determined: “The most common side effects of cannabinoids are tiredness and dizziness (in more than ten percent of patients), psychological effects, and dry mouth. Tolerance to these side effects nearly always develops within a short time. Withdrawal symptoms are hardly ever a problem in the therapeutic setting.” Authors did express concern that cannabis could pose additional health risks for adolescents and/or pregnant or breast-feeding women, as well as individuals diagnosed with Hepatitis C, severe cardiovascular disease, addictive disorders, or those vulnerable to certain psychiatric disorders, such as schizophrenia. Investigators acknowledged that cannabis dosing may adversely impact psychomotor skills. However, they noted, “Patients who take cannabinoids at a constant dosage over an extensive period of time often develop tolerance to the impairment of psychomotor performance, so that they can drive vehicles safely.” They concluded, “No acute deaths have been described that could be unequivocally attributed solely to cannabis consumption or treatment with cannabinoids.” This most recent paper follows the publication of a similar review, published in May in The Open Neurology Journal. In that paper, investigators with the University of California at San Diego and the University of California, Davis concluded: “Evidence is accumulating that cannabinoids may be useful medicine for certain indications. Based on evidence currently available, the (federal) Schedule I classification (of cannabis) is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.” In 2011, the Obama administration — via the United States Drug Enforcement Administration (DEA) — formally denied a nine-year-old administrative petition filed by NORML and a coalition of public interest organizations calling on the agency to initiate hearings to reassess the present classification of marijuana as a schedule I controlled substance. In her denial of the petition, DEA administrator Michele Leonhart alleged: “[T]here are no adequate and well-controlled studies proving (marijuana’s) efficacy; the drug is not accepted by qualified experts. … At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy.” In June, Ms. Leonhart testified before Congress that she believed that heroin and marijuana posed similar threats to the public’s health because, in her opinion, “all illegal drugs are bad.” Coalition advocates are presently appealing the DEA’s denial of their petition in federal court. Full text of the most recent study, “The therapeutic potential of cannabinoids,” is available online here.

Federal Cannabis Prohibition Turned 75-Years-Old on October 1

In a milestone that will no doubt go largely unnoticed by the mainstream media, today marks the 75th anniversary of the enactment of federal marijuana prohibition. On October 1, 1937, the US government criminally outlawed the possession and cultivation of cannabis — setting into motion a public policy that today results in some 850,000 arrests […] Read More..

Montana: Supreme Court Says Patients Possess No Fundamental Right To Cannabis

Members of the Montana Supreme Court ruled 6 to 1 on Tuesday that patients do not possess a fundamental right to access and consume cannabis for therapeutic purposes. The decision reverses a District Court ruling enjoining the state from enforcing various provisions of a 2011 state law that limits the public’s access to medical marijuana. […] Read More..

Study: Non-Psychotropic Cannabinoid “Proven To Be Safe” In Humans

The oral administration of the non-psychotropic cannabis plant constituent cannabidiol (CBD) is safe and well tolerated in humans, according to clinical trial data published online by the journal Current Pharmaceutical Design. Investigators at Kings College in London assessed the physiological and behavioral effects of CBD and THC versus placebo in 16 healthy volunteers in a […] Read More..

Michigan: Grand Rapids Voters Will Decide On $25 Fine-Only Offense For Pot Possession

Voters in Grand Rapids, Michigan will decide this November on a municipal measure to depenalize marijuana possession offenses to a non-criminal, fine-only offense. The City Commissioner’s office has approved the measure, Proposal 2, which seeks to allow local law enforcement the discretion to ticket first-time marijuana offenders with a civil citation, punishable by a $25 […] Read More..

Alternet: “Five Scientific Conclusions About Cannabis That The Mainstream Media Doesn’t Want You To Know”

Writing in the journal Science some four decades ago, New York State University sociologist Erich Goode documented the mainstream media’s complicity in maintaining cannabis prohibition. He observed: “[T]ests and experiments purporting to demonstrate the ravages of marijuana consumption receive enormous attention from the media, and their findings become accepted as fact by the public. But […] Read More..